Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Zhi Peng(Peking University), Lin Shen(Hangzhou Normal University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanfei Tai(Jiangsu Hengrui Medicine (China)), Ying Cheng(Jilin Province Tumor Hospital), Wang Feng(First Affiliated Hospital of Zhengzhou University), Linna Wang(Jiangsu Hengrui Medicine (China)), Kangsheng Gu(Anhui Medical University), Xianglin Yuan(Tongji University), Jianjun Zou(Jiangsu Hengrui Medicine (China)), Yanqiao Zhang(Harbin Medical University), Yanhong Deng(Sun Yat-sen University), Juxiang Xiao(First Affiliated Hospital of Xi'an Jiaotong University), Jia Wei(North Sichuan Medical University)
Clinical Cancer Research
March 25, 2021
10.1158/1078-0432.ccr-20-4691
Cited by 119

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687